Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5766951 | 0.95 | ALDH1A1 (0.53) | ALDH1A1ADORA2BPOLBKMT2ADHFR | |
| SCHEMBL5764058 | 0.91 | ALDH1A1 (0.51) | ALDH1A1ADORA2BPOLBKMT2ADHFR | |
| SCHEMBL5768178 | 0.90 | ALDH1A1 (0.50) | ALDH1A1ADORA2BPOLBKMT2ADHFR | |
| SCHEMBL5911660 | 0.85 | ALDH1A1 (0.52) | ALDH1A1ADORA2BPOLBKMT2ADHFR | |
| SCHEMBL5765472 | 0.85 | ALDH1A1 (0.52) | ALDH1A1ADORA2BPOLBKMT2ADHFR | |
| SCHEMBL5794417 | 0.85 | ALDH1A1 (0.52) | ALDH1A1ADORA2BPOLBKMT2ADHFR | |
| SCHEMBL5765468 | 0.85 | ALDH1A1 (0.52) | ALDH1A1ADORA2BPOLBKMT2ADHFR | |
| SCHEMBL5767175 | 0.84 | ADORA2B (0.51) | ALDH1A1ADORA2BPOLBKMT2ADHFR | |
| SCHEMBL5767076 | 0.84 | ALDH1A1 (0.47) | ALDH1A1ADORA2BPOLBKMT2ADHFR | |
| SCHEMBL5767034 | 0.84 | ADORA2B (0.50) | ALDH1A1ADORA2BPOLBKMT2ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116390-A1 | Hepatitis c virus inhibitors | LG LIFE SCIENCES LTD. (KR) | 2006-06-01 | — | — | US | disclosed |
| EP-1633725-A1 | HEPATITIS C VIRUS INHIBITORS | LG Life Sciences Ltd. (KR) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004111013-A1 | HEPATITIS C VIRUS INHIBITORS | LG LIFE SCIENCES LTD. (KR) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116390-A1 | Hepatitis c virus inhibitors | HAVCR2, LIPC, FABP1 | ALDH1A1 1058/4885ADORA2B 3114/4885POLB 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.